Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT05698888 Terminated - Multiple Myeloma Clinical Trials

Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors

Start date: November 29, 2022
Phase: Phase 1
Study type: Interventional

This study will test the safety, tolerability, and pharmacokinetics of VP301 in patients with relapsed or refractory multiple myeloma, lymphoma, or solid tumors.

NCT ID: NCT05611853 Terminated - Clinical trials for Mantle Cell Lymphoma

Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Start date: November 25, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Phase 1/2 trial to study the safety, pharmacokinetics and preliminary efficacy of BN301 given intravenously every 3 weeks.

NCT ID: NCT05354362 Terminated - Clinical trials for Relapsed/Refractory Diffuse Large B-cell Lymphoma

A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

MATCH
Start date: March 2, 2022
Phase: Phase 1
Study type: Interventional

This is an Open label, Phase Ⅰb Study of ATG-010 in Combination With ATG-008 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)

NCT ID: NCT05328102 Terminated - Clinical trials for Diffuse Large-cell B-cell Lymphoma

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in R/R DLBCL

Start date: April 25, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the safety and effectiveness of plamotamab when it is given with tafasitamab and lenalidomide in relapsed or refractory DLBCL.

NCT ID: NCT05319028 Terminated - Clinical trials for Non-GCB/ABC Diffuse Large B-Cell Lymphoma

Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Start date: June 23, 2022
Phase: Phase 2
Study type: Interventional

Study CX-659-401 is a multicenter, open-label, phase 2 study of mivavotinib to evaluate the single-agent activity of mivavotinib in patients with relapsed/refractory non-GCB/ABC DLBCL, incorporating ctDNA-based next-generation sequencing (NGS) to identify DLBCL patients harboring MyD88 and/or CD79B mutations within the study. This goal of this strategy is to evaluate its activity both in the cell-of-origin subgroup of non-GCB/ABC DLBCL and in the genetically defined subgroups of MyD88/CD79B-mutated and wild type DLBCL.

NCT ID: NCT05244070 Terminated - Lymphoma Clinical Trials

A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Start date: September 14, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and preliminary efficacy of BMS-986403 in participants with relapsed and/or refractory chronic lymphocytic leukemia (R/R CLL) or small lymphocytic lymphoma (SLL).

NCT ID: NCT05242146 Terminated - CNS Lymphoma Clinical Trials

GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma

STAR CNS
Start date: May 24, 2022
Phase: Phase 1
Study type: Interventional

The STAR CNS trial is a 3-part study, comprising a phase 1b dose escalation, dose expansion, and a phase 2, to assess the safety, tolerability, dose-limiting toxicity(ies), maximum tolerated dose, and/or optimal biological dose, determine the recommended phase 2 dose, preliminary anti-tumor activity and efficacy of the recommended phase 2 dose of GB5121.

NCT ID: NCT05222269 Terminated - CNS Lymphoma Clinical Trials

[68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients

Start date: October 5, 2022
Phase: Phase 2
Study type: Interventional

This will be an open, single-arm, international, multicentre, phase II imaging study to assess the predictive value of [68Ga]Ga PentixaFor PET imaging in primary and isolated secondary central nervous system lymphoma (CNSL) patients scheduled to undergo induction chemotherapy.

NCT ID: NCT05221385 Terminated - Solid Tumor Clinical Trials

Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma

Start date: April 12, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of gentulizumab, an anti-CD47 Monoclonal Antibody, in participants with solid tumors and non-Hodgkin lymphoma.

NCT ID: NCT05205161 Terminated - Clinical trials for Non-Hodgkin Lymphoma

A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma

Start date: July 5, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluates the safety, tolerability, PK, and preliminary efficacy of AZD0466 as monotherapy or in combination with other anticancer agents in patients with advanced NHL